OrbiMed Private Investments X drew $1.9 billion to focus on venture capital opportunities within Western markets. Simultaneously, the firm raised over $1 billion for OrbiMed Asia Partners VI, an initiative aimed at capturing growth in the region’s expanding biotechnology sector. Carl Gordon, managing partner at OrbiMed, noted that the convergence of artificial intelligence and new therapeutic modalities creates an unprecedented environment for building transformative companies.
OrbiMed Secures $3 Billion for Global Healthcare Expansion
Healthcare investment firm OrbiMed has closed two new private equity funds totaling $3 billion, signaling a major push into life sciences innovation across the U.S., Europe, and Asia. The capital will target advancements in biopharmaceuticals, medical devices, and technology-driven services through its latest venture and growth equity vehicles.
The firm manages a total of $21 billion in assets, supported by a 150-person team operating across 12 global locations. Backed by a diverse investor base that includes sovereign wealth funds, pension systems, and university endowments, the firm plans to deploy this capital toward both startups and established multinational corporations. Carter Neild, also a managing partner, emphasized that the firm intends to leverage its deep operational expertise to meet the expectations of these long-standing institutional partners.
Comments (0)
No comments yet. Be the first!